search
Back to results

Safety and Efficacy of the BTL-785F Device for Non-invasive Reduction of Submental Fat

Primary Purpose

Skin Laxity

Status
Active
Phase
Not Applicable
Locations
Bulgaria
Study Type
Interventional
Intervention
BTL-785-7
Sponsored by
BTL Industries Ltd.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Skin Laxity

Eligibility Criteria

21 Years - undefined (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria: Healthy male or female subjects over 21 years of age seeking treatment for reduction of submental fat Subjects should be able understand the investigative nature of the treatment, the possible benefits and side effects, and must sign the Informed Consent Form Presence of clearly visible excess fat in submentum as deemed appropriate by the Investigator Subjects willing and able to abstain from partaking in any facial treatments other than the study procedure during study participation Willingness to comply with study instructions, to return to the clinic for the required visits, and to have photographs of their face taken Exclusion Criteria: Local bacterial or viral infection in the area to be treated Local acute inflammation in the area to be treated Impaired immune system caused by any immunosuppressive illness, disease or medication Isotretinoin and tretinoin-containing medication use in the past 12 months Skin related autoimmune diseases Radiation therapy and/or chemotherapy Poor healing and unhealed wounds in the treatment area Metal implants Permanent implant in the treated area Pacemaker or internal defibrillator, or any other active electrical implant anywhere in the body Facial dermabrasion, facial resurfacing, or deep chemical peeling in the treatment area within 3 months prior to the treatment Current or history of skin cancer, or current condition of any other type of cancer, or pre-malignant moles History of skin disorders, keloids, abnormal wound healing and dry or fragile skin History of any type of cancer Active collagen diseases Cardiovascular diseases (such as vascular diseases, peripheral arterial disease, thrombophlebitis and thrombosis)1 Pregnancy/nursing or IVF procedure History of bleeding coagulopathies, use of anticoagulants Any active condition in the treatment area, such as sores, psoriasis, eczema, rash and rosacea Any surgical procedure in the treatment area within the last three months or before complete healing Poorly controlled endocrine disorders, such as diabetes Acute neuralgia and neuropathy Kidney or liver failure Nerve insensitivity (sensitivity disorders) to heat in the treatment area Varicose veins, pronounced edemas1 Prior use of dermal fillers, botulinum toxin, lasers, etc. therapies in the treated area that can influence the study results at the investigator discretion Unwillingness/inability to not change their usual cosmetics and especially not to use fat reduction, anti-aging or anti-wrinkles products in the treated area during the duration of the study including the follow-up period Electroanalgesia without exact diagnosis of pain etiology Neurological disorders (such as multiple cerebrospinal sclerosis, epilepsy) Blood vessels and lymphatic vessels inflammation Any other disease or condition at the investigator discretion that may pose risk to the patient or compromise the study

Sites / Locations

  • Center for specialized medical care - Individual dermatological practice Dr. Mariya Genova

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

BTL-785-7 Treatment

Arm Description

Treatment with the BTL-785F device with the BTL-785-7 applicator for non-invasive reduction of submental fat.

Outcomes

Primary Outcome Measures

Change of submental fat thickness
To gather clinical evidence that BTL-785F system equipped with BTL-785-7 applicator is able to provide reduction of submental fat thickness.

Secondary Outcome Measures

Evaluation the effect on submental skin laxity
To gather clinical evidence that BTL-785F system equipped with BTL-785-7 applicator is able to provide improved skin laxity in the submental area.
Evaluation the safety of the BTL-785F device with the BTL-785-7 applicator for non-invasive reduction of submental fat.
To evaluate the safety of the BTL-785F device with the BTL-785-7 applicator for non-invasive reduction of submental fat through monitoring of adverse reactions.

Full Information

First Posted
April 14, 2023
Last Updated
August 31, 2023
Sponsor
BTL Industries Ltd.
search

1. Study Identification

Unique Protocol Identification Number
NCT05831332
Brief Title
Safety and Efficacy of the BTL-785F Device for Non-invasive Reduction of Submental Fat
Official Title
Safety and Efficacy of the BTL-785F Device for Non-invasive Reduction of Submental Fat
Study Type
Interventional

2. Study Status

Record Verification Date
August 2023
Overall Recruitment Status
Active, not recruiting
Study Start Date
March 6, 2023 (Actual)
Primary Completion Date
August 30, 2023 (Actual)
Study Completion Date
December 31, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
BTL Industries Ltd.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This study will evaluate the clinical safety and the performance of the BTL-785F system equipped with the BTL-785-7 applicator for non-invasive reduction of submental fat and skin laxity treatment.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Skin Laxity

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
56 (Actual)

8. Arms, Groups, and Interventions

Arm Title
BTL-785-7 Treatment
Arm Type
Experimental
Arm Description
Treatment with the BTL-785F device with the BTL-785-7 applicator for non-invasive reduction of submental fat.
Intervention Type
Device
Intervention Name(s)
BTL-785-7
Intervention Description
Treatment with the BTL-785F device with the BTL-785-7 applicator for non-invasive reduction of submental fat.
Primary Outcome Measure Information:
Title
Change of submental fat thickness
Description
To gather clinical evidence that BTL-785F system equipped with BTL-785-7 applicator is able to provide reduction of submental fat thickness.
Time Frame
6 months
Secondary Outcome Measure Information:
Title
Evaluation the effect on submental skin laxity
Description
To gather clinical evidence that BTL-785F system equipped with BTL-785-7 applicator is able to provide improved skin laxity in the submental area.
Time Frame
6 months
Title
Evaluation the safety of the BTL-785F device with the BTL-785-7 applicator for non-invasive reduction of submental fat.
Description
To evaluate the safety of the BTL-785F device with the BTL-785-7 applicator for non-invasive reduction of submental fat through monitoring of adverse reactions.
Time Frame
6 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
21 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Healthy male or female subjects over 21 years of age seeking treatment for reduction of submental fat Subjects should be able understand the investigative nature of the treatment, the possible benefits and side effects, and must sign the Informed Consent Form Presence of clearly visible excess fat in submentum as deemed appropriate by the Investigator Subjects willing and able to abstain from partaking in any facial treatments other than the study procedure during study participation Willingness to comply with study instructions, to return to the clinic for the required visits, and to have photographs of their face taken Exclusion Criteria: Local bacterial or viral infection in the area to be treated Local acute inflammation in the area to be treated Impaired immune system caused by any immunosuppressive illness, disease or medication Isotretinoin and tretinoin-containing medication use in the past 12 months Skin related autoimmune diseases Radiation therapy and/or chemotherapy Poor healing and unhealed wounds in the treatment area Metal implants Permanent implant in the treated area Pacemaker or internal defibrillator, or any other active electrical implant anywhere in the body Facial dermabrasion, facial resurfacing, or deep chemical peeling in the treatment area within 3 months prior to the treatment Current or history of skin cancer, or current condition of any other type of cancer, or pre-malignant moles History of skin disorders, keloids, abnormal wound healing and dry or fragile skin History of any type of cancer Active collagen diseases Cardiovascular diseases (such as vascular diseases, peripheral arterial disease, thrombophlebitis and thrombosis)1 Pregnancy/nursing or IVF procedure History of bleeding coagulopathies, use of anticoagulants Any active condition in the treatment area, such as sores, psoriasis, eczema, rash and rosacea Any surgical procedure in the treatment area within the last three months or before complete healing Poorly controlled endocrine disorders, such as diabetes Acute neuralgia and neuropathy Kidney or liver failure Nerve insensitivity (sensitivity disorders) to heat in the treatment area Varicose veins, pronounced edemas1 Prior use of dermal fillers, botulinum toxin, lasers, etc. therapies in the treated area that can influence the study results at the investigator discretion Unwillingness/inability to not change their usual cosmetics and especially not to use fat reduction, anti-aging or anti-wrinkles products in the treated area during the duration of the study including the follow-up period Electroanalgesia without exact diagnosis of pain etiology Neurological disorders (such as multiple cerebrospinal sclerosis, epilepsy) Blood vessels and lymphatic vessels inflammation Any other disease or condition at the investigator discretion that may pose risk to the patient or compromise the study
Facility Information:
Facility Name
Center for specialized medical care - Individual dermatological practice Dr. Mariya Genova
City
Plovdiv
ZIP/Postal Code
4000
Country
Bulgaria

12. IPD Sharing Statement

Learn more about this trial

Safety and Efficacy of the BTL-785F Device for Non-invasive Reduction of Submental Fat

We'll reach out to this number within 24 hrs